Amryt Announces Positive Long-Term Safety and Efficacy Data confirming the role for Mycapssa® (oral octreotide) in the management of Acromegaly patients...
Amryt Pharma plc - Key Dates for AIM Delisting DUBLIN, Ireland, and Boston MA, January 6, 2022, Amryt Pharma plc (Nasdaq: AMYT, AIM: AMYT) (“Amryt” or the...
The Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients ...
Total Voting Rights DUBLIN, Ireland, and Boston MA, January 4, 2022, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical...
Total Voting Rights DUBLIN, Ireland, and Boston MA, December 1, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical...
Amryt Pharma plc Director/PDMR Shareholding The following notification is made in accordance with the requirements of the EU Market Abuse Regulation (as...
Amryt Provides Update on Regulatory Review Process for Oleogel-S10 FDA PDUFA goal date extended by three months to February 28, 2022 EMA CHMP opinion now...
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 WHICH FORMS PART OF DOMESTIC...
Amryt Reports Strong Q3 2021 Results 14.6% YoY revenue growth in Q3 to $56.5M 21.5% growth in metreleptin revenues YoY to $36.3M in Q3; 51.6% growth YoY...
Amryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3 DUBLIN, Ireland, and Boston MA, October 20, 2021, Amryt (Nasdaq:...